Pharmacy Times August 7, 2024
Alana Hippensteele, Managing Editor

Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.

The commonalities between type 2 diabetes (T2D) and neurodegenerative disorders have gained increasing attention in terms of treatment opportunities, explained Nigel H. Greig, PhD, a senior investigator in the Translational Gerontology Branch at the National Institute of Health, during a presentation at the 2024 Alzheimer’s Association International Conference (AAIC) in Philadelphia, Pennsylvania. Notably, commonalities in cell death pathways between these conditions suggest that treatments effective in one may also benefit the other, according to Greig.1

Among the promising therapeutic candidates are glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, which have shown potential in reducing the risk of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, Patient / Consumer, Pharma / Biotech, Provider, Trends
Related Articles:
Navigating Complex Regulatory Landscapes in the Biopharmaceutical Industry
How Life Sciences Can Drive Innovation And Sustainability In Returns Management
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
How Americans feel about weight-loss drugs, in 3 charts
Tariffs on China threaten could drive up drug costs, exacerbate shortages: 5 notes

Share This Article